Cannell & Co’s Biogen BIIB Stock Holding History

Cannell & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,028	Closed	-$292K	–	272
2020 Q3	$292K	Hold	1,028	–	–	0.01%	219
2020 Q2	$275K	Sell	1,028 -150	-13%	-$45.1K	0.01%	214
2020 Q1	$373K	Buy	1,178 +58	+5%	+$17.6K	0.02%	189
2019 Q4	$332K	Buy	+1,120	New	+$311K	0.01%	208

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cannell & Co's BIIB Position: Q4 2020 in Review

Cannell & Co sold out of Biogen (BIIB) in Q4 2020, closing a stake of 1,028 shares — an estimated $292K sold.

Cannell & Co first reported a position in BIIB in Q4 2019 and held it in 4 quarters. The position peaked at $373K in Q1 2020. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

Cannell & Co reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
Cannell & Co sold 1,028 Biogen shares in Q4 2020, an estimated $292K.
Cannell & Co first reported a position in Biogen in Q4 2019 and held it in 4 quarters.
Cannell & Co's Biogen position peaked at $373K in Q1 2020.
1,062 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Cannell & Co's 13F filing for Q4 2020, filed 11 Feb 2021.